Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT05911360

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

Conditions: HIV, HIV Infections

Sex: All

Ages: 50 Years – N/A

Healthy volunteers: No

Phase: PHASE3

Enrollment: 205

Sponsor: ViiV Healthcare

Location: GSK Investigational Site Phoenix Arizona

Summary

The study aims at evaluating the maintenance of virologic suppression of dolutegravir/lamivudine (DTG/3TC) fixed dose combination (FDC) at Week 48 post-switch from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in participants living with Human Immunodeficiency Virus Type 1 (HIV-1) who are of at least 50 years of age and above.

Eligibility Criteria

Inclusion Criteria: * Participants living with HIV-1 and had documented plasma HIV-1 RNA \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05911360). StuddyBuddy aggregates publicly available trial information.